The report is not positive for the drug middlemen, which immediately criticized it as one-sided.| Healthcare Dive
The major PBM said its lawsuit is necessary to protect against misinformation about the controversial drug middlemen, while the FTC promised to defend its research.| Healthcare Dive
Congress is inching closer to pharmacy benefit manager reform with new legislation released last week. But even eliminating all PBM profits would barely move the needle on U.S. drug spending, according to a new report.| Healthcare Dive